[1] Tresoldi C,Pellegata AF,Mantero S.Cells and stimuli in small-caliber blood vessel tissue engineering[J].Regen Med,2015,10(4):505~527. [2] Zhang H,Jia X,Han F,et al.Dual-delivery of VEGF and PDGF by double-layered electrospun membranes for blood vessel regeneration[J].Biomaterials,2013,34(9):2202~2212. [3] Opitz F,Schenke-Layland K,Richter W,et al.Tissue engineering of ovine aortic blood vessel substitutes using applied shear stress and enzymatically derived vascular smooth muscle cells[J].Ann Biomed Eng,2004,32(2):212~222. [4] Paudel KR,Karki R,Kim DW.Cepharanthine inhibits in vitro VSMC proliferation and migration and vascular inflammatory responses mediated by RAW264.7[J].Toxicol In Vitro,2016,34:16~25. [5] Yu H,Clarke MC,Figg N,et al.Smooth muscle cell apoptosis promotes vessel remodeling and repair via activation of cell migration,proliferation,and collagen synthesis[J].Arterioscler Thromb Vasc Biol,2011,31(11):2402~2409. [6] Chen S,Ding Y,Tao W,et al.Naringenin inhibits TNF-αinduced VSMC proliferation and migration via induction of HO-1[J].Food Chem Toxicol,2012,50(9):3025~3031. [7] Douchi D,Ohtsuka H,Ariake K,et al.Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/β-catenin signaling pathway[J].Cancer Lett,2015,365(1):132~140. [8] Chen WC,Wang CY,Hung YH,et al.Systematic analysis of gene expression alterations and clinical outcomes for long-chain acyl-coenzyme a synthetase family in cancer[J].PLoS One,2016,11(5):e0155660. [9] Choe N,Kwon JS,Kim JR,et al.The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia[J].Atherosclerosis,2013,229(2):348~355. [10] Li WQ,Yu HY,Li YM,et al.Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide,a type II topoisomerase inhibitor[J].Biochem Biophys Res Commun,2014,446(4):1261~1267. [11] Li Y,Li W,Yang Y,et al.MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme[J].Brain Res,2009,1286:13~18. [12] Ye Y,Perez-Polo JR,Qian J,et al.The role of microRNA in modulating myocardial ischemia-reperfusion injury[J].Physiol Genomics,2011,43(10):534~542. [13] Greliche N,Zeller T,Wild PS,et al.Comprehensive exploration of the effects of miRNA SNPs on monocyte gene expression[J].PLoS One,2012,7(9):e45863. [14] Adlakha YK,Saini N.Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128[J].moL Cancer,2014,13:33. [15] Loyer X,Mallat Z,Boulanger CM,et al.MicroRNAs as therapeutic targets in atherosclerosis[J].Expert Opin Ther Targets,2015,19(4):489~496. [16] Lee HJ.Additional stories of microRNAs[J].Exp Biol Med(Maywood),2014,239(10):1275~1279. [17] Connerty P,Ahadi A,Hutvagner G.RNA Binding Proteins in the miRNA Pathway[J].Int moL Sci,2015,17(1). [18] Climent M,Quintavalle M,Miragoli M,et al.TGFβtriggers miR-143/145 transfer from smooth muscle cells to endothelial cells,thereby modulating vessel stabilization[J].Circ Res,2015,116(11):1753~1764. [19] Wang YS,Li SH,Guo J,et al.Role of miR-145 in cardiac myofibroblast differentiation[J].moL Cell Cardiol,2014,66:94~105. [20] Liu X,Cheng Y,Yang J,et al.Flank sequences of miR-145/143 and their aberrant expression in vascular disease:mechanism and therapeutic application[J].Am Heart Assoc,2013,2(6):e000407. [21] Ji LY,Jiang DQ,Dong NN.The role of miR-145 in microvasculature[J].Pharmazie,2013,68(6):387~391. [22] Shimizu C,Kim J,Stepanowsky P,et al.Differential expression of miR-145 in children with Kawasaki disease[J].PLoS One,2013,8(3):e58159.
2017, Vol. 23 
冀公网安备13080202000677号